COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Impact of Microparticles in Blood on Transfused Patient Outcomes (IMIB)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03041974
Recruitment Status : Completed
First Posted : February 3, 2017
Last Update Posted : February 3, 2017
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Besancon

Brief Summary:
During storage, red blood cells (RBCs) undergo changes collectively termed "Storage lesions". these changes may have an impact of the outcomes of transfused patients. One of these changes is the release of microparticles by RBCs and other blood cells types. The aim of the study is to (1) quantify red cell- and platelet-derived microparticles in RBC concentrates, and (2) evaluate the impact of transfused microparticles (MPs) on survival and post-transfusion complications in critical care patients participating in the ABLE trial (ISRCTN44878718).

Condition or disease Intervention/treatment
Critical Care Procedure: Red Blood Cell transfusion Procedure: Microparticles quantification

Detailed Description:

During conservation of red blood cell concentrates, red blood cells (RBCs) undergo biochemical and morphological changes that have been well described, and are collectively termed " storage lesions ". The exact effects of these lesions in terms of beneficial or deleterious implications in the recipient remain to be elucidated. However, several retrospective studies in targeted populations suggest that an increase in the duration of RBC conservation could lead to an increase in morbidity and mortality in transfused patients. The multicenter, prospective trial ABLE (Age of Blood Evaluation, ISRCTN44878718) aimed to evaluate in a randomised clinical trial, the impact of the age of transfused RBC concentrates on several outcomes in critical care patients.

Among the modifications that RBCs undergo during storage, the generation of microparticles from red blood cellsRBCs or residual platelets present in the blood concentrate has never been evaluated in a prospective clinical study. It has been reported that the number of red cell-derived microparticles (RMPs) present in stored blood increases with storage duration. In vivo, microparticles MPs appear to be increasingly involved in disease processes, notably due to their pro-inflammatory and pro-coagulant effects. Furthermore, it has been shown that the antigens of the Rhesus group are expressed on the RBC derived microparticles, and the investigative team has shown that microparticles derived from elsewhere (endothelial cells) are capable of activating cells which are important in the induction of immune responses (dendritic cells). Thus, transfusing red blood cell derived microparticles could participate in post-transfusional alloimmunization which may also be evaluated in this study.

The aim of the IMIB study is to (1) quantify red cell- and platelet-derived microparticles MPs in RBC concentrates, and (2) evaluate the impact of the quantity of transfused microparticles (MPs) on survival and several outcomes in the patients enrolled in the ABLE trial in France.

Other aims are to investigate the relationship between the number of microparticles in RBC units and (1) the age of RBC, (2) donors characteristics, (3) the procedures used to prepare the blood products (to define a potential new "lesion storage" marker).

Layout table for study information
Study Type : Observational
Actual Enrollment : 280 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Cell-derived Microparticles in Red Blood Cell (RBC) Concentrates, and Their Potential Impact on Outcomes of Transfused Patients in Critical Care: a Prospective Multicentre National Cohort Study of Patients Included in the ABLE Trial
Study Start Date : March 2011
Actual Primary Completion Date : May 2014
Actual Study Completion Date : November 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Critical Care

Group/Cohort Intervention/treatment
Transfused critical care patients
Patients included in the Age of BLood Evaluation (ABLE) trial in either arms and included in a French center.
Procedure: Red Blood Cell transfusion
Procedure: Microparticles quantification
Flow cytometric quantification of microparticles in transfused blood

Primary Outcome Measures :
  1. All cause mortality [ Time Frame: 90 days ]

Secondary Outcome Measures :
  1. All cause mortality [ Time Frame: 28 days, 6 months ]
  2. Multi organ dysfunction score [ Time Frame: 6 months ]
  3. Nosocomial infection [ Time Frame: 6 months ]
    including Nosocomial pneumonia, Deep tissue infections (e.g. peritonitis, mediastinitis), Bacteraemia from organisms not considered normal skin flora and judged important enough to treat by the attending team, as measured while in the ICU

Other Outcome Measures:
  1. Intensive care and Hospital duration of stay [ Time Frame: 6 months ]
  2. Length of time requiring respiratory, haemodynamic and renal support [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The patients included in the study are the patients enrolled, by french centers, in either arms of the ABLE trial.

Inclusion Criteria are those of the ABLE trial: patients who

  • Have had a request for a first red cell unit transfusion in the Intensive Care Unit (ICU), and
  • Have an anticipated length of invasive and/or non-invasive continuous positive airway pressure (CPAP) or bi-level positive airway pressure (BIPAP) mechanical ventilation of at least 48 hours once enrolled, as estimated by the attending physician

Exclusion Criteria:

  • less than 18 years of age
  • previously enrolled in the ABLE study
  • has already been transfused with red cells during the current hospitalisation
  • has an obvious terminal illness documented in the medical record with a life expectancy of less than 3 months
  • has undergone routine cardiac surgical care
  • decision to withdraw/withhold some critical care had been made
  • brain dead
  • no red cells with a storage time of 7 days or less available in the blood bank that cannot be transported from the blood supplier
  • Who require more than 1 unit of uncross-matched red cells
  • With a known objection to blood transfusions
  • With autologous blood donations
  • Who pose difficulties in securing blood products (rare blood groups), and who are difficult to match

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03041974

Sponsors and Collaborators
Centre Hospitalier Universitaire de Besancon
Layout table for investigator information
Principal Investigator: Francine Garnache-Ottou, PharmD, PhD Etablissement Français du Sang, Besançon
Layout table for additonal information
Responsible Party: Centre Hospitalier Universitaire de Besancon Identifier: NCT03041974    
Other Study ID Numbers: IMIB PHRC 2013
First Posted: February 3, 2017    Key Record Dates
Last Update Posted: February 3, 2017
Last Verified: February 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Centre Hospitalier Universitaire de Besancon:
Red Blood Cell Transfusion
Cell-Derived Microparticles